阿苯达唑治疗囊型棘球蚴病的研究进展

doi:10.16431/j.cnki.1671-7236.2026.02.004

Abstract

Abstract:

Cystic echinococcosis （CE）， a severe zoonotic parasitic disease caused by the larval stage of Echinococcus granulosus （Eg）， primarily affects human and livestock liver and lung tissues. Current treatment primarily involves surgical removal of cystic lesions combined with chemotherapy. However， traditional medications such as mebendazole（MBZ） and albendazole（ABZ） only inhibit parasite growth and reproduction without complete eradication， requiring long-term high-dose administration which can lead to adverse reactions including hepatotoxicity. Recent research has focused on novel ABZ formulations， delivery systems， and combination therapy strategies. Novel formulations and delivery methods aim to enhance efficacy by improving bioavailability and reducing toxicity： Emulsions and salt preparations optimize drug solubility， while ABZ combined with nanoparticles or carriers （liposomes and chitosan） creates targeted delivery systems that increase local drug concentration while minimizing systemic toxicity. Combination therapies demonstrate synergistic effects through multi-mechanism interference with parasite metabolism， combining ABZ with drugs such as praziquantel， flubendazole， and α-interferon. Despite these advances， no breakthrough therapeutic alternatives have emerged. This review summarizes the research progress of ABZ in treating CE， analyzing the advantages and limitations of various treatment approaches to provide a scientific basis for future drug development and clinical treatment optimization.

Key words: cystic echinococcosis（CE）; albendazole（ABZ）; novel formulations; novel delivery methods; combination therapy

CLC Number:

S859.79⁺5

SONG Runrun, ZHANG Huan, LUOSANG Quzhen, CI Puchi, ZHANG Nianzhang. Research Progress of Albendazole in the Treatment of Cystic Echinococcosis[J]. China Animal Husbandry & Veterinary Medicine, 2026, 53(2): 555-563.

References 50

[1]	WEN H， VUITTON L， TUXUN T， et al. Echinococcosis： Advances in the 21st century［J］. Clinical Microbiology Reviews， 2019， 32（2）： e00075-18.
[2]	王旭，王莹，刘白雪，等.棘球绦虫和棘球蚴病的简明认知历史［J］.中国寄生虫学与寄生虫病杂志， 2024， 42（3）： 372-383.
	WANG X， WANG Y， LIU B X， et al. A brief cognitive and historical overview of Echinococcus and echinococcosis［J］. Chinese Journal of Parasitology and Parasitic Diseases， 2024， 42（3）： 372-383. （in Chinese）
[3]	代国栋，闫鸿斌，李立，等.人兽共患寄生虫病候选疫苗分子筛选方法研究进展［J］.中国畜牧兽医， 2021， 48（6）： 2177-2187.
	DAI G D， YAN H B， LI L， et al. Research progress on screening methods for candidate vaccine molecules against parasitic zoonoses［J］. China Animal Husbandry & Veterinary Medicine， 2021， 48（6）： 2177-2187.（in Chinese）
[4]	WOOLSEY I D， MILLER A L. Echinococcus granulosus sensu lato and Echinococcus multilocularis： A review［J］. Research in Veterinary Science， 2021， 135： 517-522.
[5]	尚婧晔，张光葭，何伟，等.细粒棘球蚴病病原分类学与分子流行病学研究进展［J］.中国寄生虫学与寄生虫病杂志， 2018， 36（2）： 166-173.
	SHANG J Y， ZHANG G J， HE W， et al. Taxonomy and molecular epidemiology of Echinococcus granulosus complex causing cystic echinococcosis［J］. Chinese Journal of Parasitology and Parasitic Diseases， 2018， 36（2）： 166-173.（in Chinese）
[6]	赵文卿，薄新文，普娜，等.细粒棘球绦虫EgBAL蛋白的生物信息学分析及原核表达［J］.中国畜牧兽医，2025， 52（2）： 801-810.
	ZHAO W Q， BO X W， PU N， et al. Bioinformatics analysis and prokaryotic expression of EgBAL protein of Echinococcus granulosus ［J］. China Animal Husbandry & Veterinary Medicine， 2025， 52（2）： 801-810.（in Chinese）
[7]	AGUDELO HIGUITA N I， BRUNETTI E， MCCLOSKEY C， et al. Cystic echinococcosis［J］. Journal of Clinical Microbiology， 2016， 54（3）： 518-523.
[8]	许少全，麦尔哈巴·麦麦提艾力，吕国栋，等.细粒棘球绦虫PCNA蛋白生物信息学分析及验证［J］.中国畜牧兽医， 2024， 51（11）： 4956-4963.
	XU S Q， MAI M H， LYU G D， et al. Bioinformatics analysis and validation of PCNA protein in Echinococcus granulosus sesensu lato ［J］. China Animal Husbandry & Veterinary Medicine， 2024， 51（11）： 4956-4963.（in Chinese）
[9]	朱文君，韩秀敏，郭亚民.苯并咪唑类药物治疗包虫病研究进展［J］.中国血吸虫病防治杂志， 2017， 29（4）： 4.
	ZHU W J， HAI X M， GUO Y M. Progress in researches of benzimidazole in treatment of echinococcosis［J］. Chinese Journal of Schistosomiasis Control， 2017， 29（4）： 4.（in Chinese）
[10]	CHAI J Y， JUNG B K， HONG S J. Albendazole and mebendazole as anti-parasitic and anti-cancer agents： An update［J］. The Korean Journal of Parasitology， 2021， 59（3）： 189-225.
[11]	DAYAN A D. Albendazole， mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics［J］. Acta Tropica， 2003， 86（2-3）： 141-159.
[12]	PÉREZ-SERRANO J， DENEGRI G， CASADO N， et al. Anti-tubulin immunohistochemistry study of Echinococcus granulosus protoscolices incubated with albendazole and albendazole sulphoxide in vitro ［J］. Parasitology Research， 1995， 81（5）： 438-440.
[13]	XIN Q， YUAN M， LI H， et al. In vitro and in vivo effects of 3-bromopyruvate against Echinococcus metacestodes ［J］. Veterinary Research， 2019， 50（1）： 96.
[14]	张鸿，何健，陈宁.脂肪乳剂在静脉麻醉药物中的应用［J］.武警医学院学报， 2009， 18（3）： 256-259.
	ZHANG H， HE J， CHEN N. Application of fat emulsions in intravenous anesthetics［J］. Journal of Medical College of Chinese People’s Armed Police Forces， 2009， 18（3）： 256-259.（in Chinese）
[15]	WANG M J， XIAO S H， CHAI J J， et al. Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis： Evaluation of bioavailability and bioequivalence［J］. Acta Tropica， 2002， 83（2）： 177-181.
[16]	XIAO S H， YOU J Q， WANG M J， et al. Augmented bioavailability and cysticidal activity of albendazole reformulated in soybean emulsion in mice infected with Echinococcus granulosus or Echinococcus multilocularis ［J］. Acta Tropica， 2002， 82（1）： 77-84.
[17]	王振军，冯丹，丁卓玲.盐基不同的盐类药物临床应用的比较分析［J］.中国医院药学杂志， 2010， 30（15）： 1305-1308.
	WANG Z J， FENG D， DING Z L.Comparative analysis of the clinical application of salts with different bases［J］.Chinese Journal of Hospital Pharmacy， 2010， 30（15）： 1305-1308.（in Chinese）
[18]	VURAL G， YARDIMCI M， KOCAK M， et al. Efficacy of novel albendazole salt formulations against secondary cystic echinococcosis in experimentally infected mice［J］. Parasitology， 2020， 147（13）： 1425-1432.
[19]	ULLIO GAMBOA G V， PENSEL P E， ELISSONDO M C， et al. Albendazole-lipid nanocapsules： Optimization， characterization and chemoprophylactic efficacy in mice infected with Echinococcus granulosus ［J］. Experimental Parasitology， 2019， 198： 79-86.
[20]	PENSEL P E， ULLIO GAMBOA G， FABBRI J， et al. Cystic echinococcosis therapy： Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice［J］. Acta Tropica， 2015， 152： 185-194.
[21]	FAIZI F， MAHJUB R， TORABI N， et al. Cationized albumin conjugated solid lipid nanoparticles as vectors for delivery of albendazole against cystic echinococcosis［J］. Parasites & Vectors， 2024， 17（1）： 542.
[22]	JAFERNIK K， LADNIAK A， BLICHARSKA E， et al. Chitosan-based nanoparticles as effective drug delivery systems—A review［J］. Molecules， 2023， 28（4）： 1963.
[23]	TORABI N， DOBAKHTI F， FAGHIHZADEH S， et al. In vitro and in vivo effects of chitosan-praziquantel and chitosan-albendazole nanoparticles on Echinococcus granulosus metacestodes ［J］. Parasitology Research， 2018， 117（7）： 2015-2023.
[24]	DARVISHI M M， MOAZENI M， ALIZADEH M， et al. Evaluation of the efficacy of albendazole sulfoxide （ABZ-SO）-loaded chitosan-PLGA nanoparticles in the treatment of cystic echinococcosis in laboratory mice［J］. Parasitology Research， 2020， 119（12）： 4233-4241.
[25]	ALBALAWI A E， ALANAZI A D， BAHARVAND P， et al. High potency of organic and inorganic nanoparticles to treat cystic echinococcosis： An evidence-based review［J］. Nanomaterials， 2020， 10（12）： 2538.
[26]	NOROUZI R， ATAEI A， HEJAZY M， et al. Scolicidal effects of nanoparticles against hydatid cyst protoscolices in vitro ［J］. International Journal of Nanomedicine， 2020， 15： 1095-1100.
[27]	NASSEF N E， SAAD A E， HARBA N M， et al. Evaluation of the therapeutic efficacy of albendazole-loaded silver nanoparticles against Echinococcus granulosus infection in experimental mice［J］. Journal of Parasitic Diseases， 2019， 43（4）： 658-671.
[28]	SRIVASTAVA I K， VAIDYA A B. A mechanism for the synergistic antimalarial action of atovaquone and proguanil［J］. Antimicrobial Agents and Chemotherapy， 1999， 43（6）： 1334-1339.
[29]	LI Q， LIU T， LV K， et al. Malaria： Past， present， and future［J］. Signal Transduction and Targeted Therapy， 2025， 10（1）： 188.
[30]	GOUDARZI F， JAJARMI V， SHOJAEE S， et al. Formulation and evaluation of atovaquone-loaded macrophage-derived exosomes against Toxoplasma gondii： In vitro and in vivo assessment［J］. Microbiology Spectrum， 2024， 12（1）： e0308023.
[31]	GONG Y， ZHOU T， MA R， et al. Efficacy and mechanism of energy metabolism dual-regulated nanoparticles （atovaquone-albendazole nanoparticles） against cystic echinococcosis［J］. BMC Infectious Diseases， 2024， 24（1）： 778.
[32]	KHATOON H， FAUDZI S M M， SOHAJDA T. Mechanisms and therapeutic applications of β-cyclodextrin in drug solubilisation and delivery systems［J］. Chemistry & Biodiversity， 2025， 5： e00359
[33]	WANG H， LI J， ZHANG C， et al. Echinococcus granulosus sensu stricto： Silencing of thioredoxin peroxidase impairs the differentiation of protoscoleces into metacestodes［J］. Parasite， 2018， 25： 57.
[34]	BAKHTIAR N M， AKBARZADEH A， AHMADPOUR E， et al. In vitro efficacy of albendazole-loaded β-cyclodextrin against protoscoleces of Echinococcus granulosus sensu stricto ［J］. Experimental Parasitology， 2022， 243： 108428.
[35]	JOSHI K， MAZUMDER B， CHATTOPADHYAY P， et al. Graphene family of nanomaterials： Reviewing advanced applications in drug delivery and medicine［J］. Current Drug Delivery， 2019， 16（3）： 195-214.
[36]	LASHKARIZADEH M R， SHAFIE’EI M， LASHKARIZADEH M， et al. Assessment of the effects of albendazole-loaded sulfonated graphene oxide on Echinococcus granulosus protoscoleces： An in vitro investigation［J］. Journal of Tropical Medicine， 2024， 2024（1）： 4851392.
[37]	MARSHALL I， EDWARDS G T. The effects of sustained release praziquantel on the survival of protoscolices of Echinococcus granulosus equinusin laboratory mice［J］. Annals of Tropical Medicine & Parasitology， 2016， 76（6）： 649-651.
[38]	COBO F， YARNOZ C， SESMA B， et al. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatidosis caused by Echinococcus granulosus ［J］. Tropical Medicine & International Health， 2002， 3（6）： 462-466.
[39]	POPOVA G， VUCHEV D， ANICHINA K. Treatment of hepatic and pulmonary hydatidosis with albendazole and praziquantel［J］. Helminthologia， 2023， 60（3）： 221-226.
[40]	LONGLEY D B， HARKIN D P， JOHNSTON P G. 5-fluorouracil： Mechanisms of action and clinical strategies［J］. Nature Reviews Cancer， 2003， 3（5）： 330-338.
[41]	PENSEL P E， ELISSONDO N， GAMBINO G， et al. Experimental cystic echinococcosis therapy： In vitro and in vivo combined 5-fluorouracil/albendazole treatment［J］. Veterinary Parasitology， 2017， 245： 62-70.
[42]	DEAN S R， MEOLA R W， MEOLA S M， et al. Mode of action of lufenuron on larval cat fleas （Siphonaptera： Pulicidae）［J］. Journal of Medical Entomology， 1998， 35（5）： 720-724.
[43]	THOMPSON R C A. Biology and systematics of Echinococcus ［J］. Advances in Parasitology， 2017， 95： 65-109.
[44]	BREIJO M， ISNARDI F， BRAUER M， et al. An insect growth inhibitor-lufenuron-enhances albendazole activity against hydatid cyst［J］. Veterinary Parasitology， 2011， 181（2-4）： 341-344.
[45]	UZÉ G， TAVERNIER J. High efficiency targeting of IFN-α activity： Possible applications in fighting tumours and infections［J］. Cytokine & Growth Factor Reviews， 2015， 26（2）： 179-182.
[46]	ZHANG S， ZHOU Y， SU L， et al. In vivo evaluation of the efficacy of combined albedazole-IFN-α treatment for cystic echinococcosis in mice［J］. Parasitology Research， 2016， 116（2）： 735-742.
[47]	REN J， ZHENG C， FENG G， et al. Inhibitory effect of extract of fungi of Huaieron hepatocellular carcinoma cells［J］. Journal of Huazhong University of Science and Technology， 2009， 29（2）： 198-201.
[48]	LV H， JIANG Y， LIAO M， et al. In vitro and in vivo treatments of Echinococcus granulosus with Huaier aqueous extract and albendazole liposome［J］. Parasitology Research， 2012， 112（1）： 193-198.
[49]	ASHOKKUMAR K， MURUGAN M， DHANYA M K， et al. Botany， traditional uses， phytochemistry and biological activities of cardamom ［Elettaria cardamomum （L.） Maton］—A critical review［J］. Journal of Ethnopharmacology， 2020， 246： 112244.
[50]	ALMOHAMMED H I， ALKHAIBARI A M， ALANAZI A D. Antiparasitic effects of Elettaria cardamomum L. essential oil and its main compounds， 1-8 cineole alone and in combination with albendazole against Echinococcus granulosus protoscoleces ［J］. Saudi Journal of Biological Sciences， 2022， 29（4）： 2811-2818.

Research Progress of Albendazole in the Treatment of Cystic Echinococcosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 50

Related Articles 1

Recommended Articles

Metrics

Comments